NCT01389193View on ClinicalTrials.gov

Ibudilast in the Treatment of Patients With Chronic Migraine.

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Migraine Headache
Interventions
DRUG

Ibudilast

Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks

DRUG

Placebo

Placebo 40 mg twice daily oral capsules for a duration of 8 weeks

Trial Locations (1)

Unknown

School of Medical sciences, University of Adelaide, Adelaide

Sponsors
All Listed Sponsors
collaborator

The Ministry of Science, Technology and Innovation, Denmark

OTHER_GOV

collaborator

Migraine Research Foundation

OTHER

lead

Parisa Gazerani

OTHER